Galmed's stock rockets up as execs tout a mixed set of NASH data
Shares of yet another NASH hopeful are rocketing north this morning, with Tel Aviv-based Galmed posting news on its Phase IIb fatty liver disease drug. Although the data are exciting some investors, the results were also distinctly mixed, raising some doubts about the sudden enthusiasm.
The company, which reported a flop for the rollout of its last NASH trial, today reported top-line, 52-week results from a global study testing its drug Aramchol in a high dose (600 mg) and lower dose (400 mg), alongside a placebo. The goal was to cut down liver fat, with the secondary endpoints shooting for a reduction in scarring (fibrosis) and NASH resolution. The lower dose met the primary endpoint, the company said, posting a statistically significant reduction in liver fat vs. placebo (p=0.0450). The high dose did not.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters